Defining the Urethritis Syndrome in Men Using Patient Reported Symptoms by Jordan, Stephen J. et al.
 Defining the Urethritis Syndrome in Men Using Patient Reported Symptoms 
Stephen J. Jordan
1
, Kristal J. Aaron
1
, Jane R. Schwebke
1
, Barbara J. Van Der Pol
1
,
Edward W. Hook, III
1
1
Department of Medicine, University of Alabama at Birmingham School of Medicine, 
Birmingham, AL 
Address correspondence to Stephen J. Jordan: Indiana University, 635 Barnhill Drive, 
Van Nuys Medical Science Bldg, MS 224E, Indianapolis, Indiana 46202. Phone:  1 (317) 
274-8110. Fax:  1 (317) 274-1008. E-mail: jordansj@iu.edu.
Short Summary: 30 words (Max 30) 
We evaluated the performance of seven self-reported symptoms in men with and without 
urethritis. Discharge and dysuria were associated with urethritis. Other symptoms, including 
urinary frequency and odor performed poorly. 
To evaluate self-reported symptoms to guide urethritis diagnosis, symptomatic men being 
evaluated for urethritis were asked about seven symptoms captured during history-taking. 
Discharge and dysuria were significantly associated with urethritis and, when combined with 
genital irritation and itching, identified 95% of urethritis cases; odor and urinary frequency 
performed poorly. 
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Urethritis is the most common genitourinary syndrome in  sexually active men less than 50 years 
of age
1
 with an estimated 2.8 million cases occurring annually in the United States.
2
 Urethritis is 
associated with a number of etiological agents
3
 including Neisseria gonorrhoeae (NG), 
Chlamydia trachomatis (CT), and Mycoplasma genitalium and causes a wide variety of 
symptoms, which include discharge, dysuria, localized pruritus, and penile tingling.
2, 4-7
 To 
collect information on urethral symptoms, healthcare providers often use standardized data 
collection forms, driven by the rapid adoption of electronic medical records (EMR).
8
 A result is 
that they may be both time consuming and inefficient as they encompass symptoms of both 
urinary tract infections (e.g. frequency, odor, etc) and sexually transmitted infections (e.g. 
discharge, dysuria, etc).
9
 To our knowledge, there are no recent data on the relative importance 
of specific symptoms in predicting urethritis syndrome, which  could help “re-calibrate” modern 
syndromic management approaches to urethritis. Given the increasing trend in sexually 
transmitted infection (STI) rates
10, 11
 and utilization of healthcare resources,
12
 such information 
could increase clinical efficiency by reducing unnecessary questioning and by shortening 
screening forms seeking urethritis symptoms. To this end, we evaluated 384 men attending a 
Birmingham, Alabama, STD Clinic and used data from the clinic’s EMR and urethral Gram stain 
smears to diagnose symptomatic urethritis.  Our primary objective was to test the performance of 
specific symptoms at accurately predicting urethritis. A secondary outcome was to compare our 
findings to an expert clinician-ranked survey of urethritis symptoms that predict urethritis in 
order to assess the accuracy of clinicians at predicting urethritis by syndromic management.  
  We enrolled 384 participants of whom 194 (51%) had at least one of the seven potential 
EMR urethritis symptoms (discharge, dysuria, urinary frequency, genital irritation, genital 
itching, genital lesions, and odor) captured on the EMR and were included in this study. All 
participants answered the same seven questions, none of which were specifically listed when 
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recruiting for the study. Participants were enrolled as part of a larger diagnostic study of non-
gonococcal urethritis (NGU) in men19 years of age, which included a detailed symptoms 
questionnaire and collection of a urethral swab for STI pathogen testing. All procedures were 
reviewed and approved by the local and NIH internal review processes and informed content was 
obtained for all men prior to enrollment. Men were 19 to 65 years old and 93% were black. 
Physical exams were performed by trained clinicians to determine the presence of urethral 
discharge and a urethral swab was obtained from all men for Gram stain testing of urethral 
secretions.  Gram stains were read in blinded fashion by a single expert microscopist (JRS). 139 
(64%) men were diagnosed with symptomatic urethritis based upon the presence of self-reported 
symptoms and either a discharge on physical exam (N = 106) or the presence of ≥5 
polymorphonuclear cells per high-power field (PMNs/HPF) by microscopy of a Gram stain 
smear of urethral secretions (N = 124).  Using nucleic acid amplification testing, 33 (17%) 
participants were positive for NG, 35 (18%) had positive tests for CT, and 19 (10%) had tests 
positive for both NG and CT.  Then, we compared the results to a survey from 13 experienced 
sexual health clinicians, all leaders in the STI field, who were asked to rank the seven EMR 
symptoms in order of importance for predicting urethritis using a linear 1 (most important) to 7 
(least important) scale. 
As shown in Table 1, in the 194 symptomatic men, urethral discharge was the most 
common complaint (61%), followed by dysuria (50%), genital irritation and lesions (both 10%), 
then urinary frequency and genital itching (both 7%), and then odor (1%). 139 (72%) of the 
symptomatic men were subsequently diagnosed with documented urethritis. In men with 
symptomatic urethritis, discharge was the most common symptom (71%), followed by dysuria 
(59%). All other symptoms were present in 6% of men with urethritis. Stratified by GC 
urethritis or NGU, discharge was present in 88% of men with GC urethritis and 58% of men with 
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NGU. Dysuria was present in 75% of men with GC urethritis and 47% of men with NGU. The 
other symptoms were present in 9% of men with either GC urethritis or NGU (data not shown). 
Compared to men without urethritis, discharge or dysuria were significantly associated with a 2-
fold increased risk for urethritis. In contrast, the other symptoms were independently either not 
associated with urethritis (frequency, itching or odor) or had an approximately 4-fold negative 
association with urethritis (lesions, irritation). We then used our study findings and the expert 
survey responses to determine the contribution of each symptom to accurate syndromic diagnosis 
of urethritis.  All 13 surveyed expert clinicians identified either discharge (n = 9, 69%) or dysuria 
(n = 4, 31%) as the most important symptom predicting urethritis and all identified the other 
symptom (either dysuria or discharge) as the second most important (data not shown). The mean 
expert-ranked score and standard deviation for each symptom, from most to least important, 
were discharge (1.3 ± 0.48), dysuria (1.7 ± 0.48), urinary frequency (3.8 ± 1.14), genital irritation 
(4.1 ± 0.76), genital itching (mean 4.6 ± 1.12), genital lesions (5.9 ± 1.04), and odor (6.5 ± 0.78).   
Given the strong association between dysuria or discharge and urethritis and our 
observation that almost half of men with symptomatic urethritis (n = 67, 48%) complained of 
more than one symptom (data not shown), we then calculated the proportion of documented 
urethritis diagnoses that could be identified by taking a step-wise combination approach to utility 
of urethritis symptoms. As shown in Table 2, the addition of self-reported dysuria to a discharge 
complaint captured an additional 22 (16%) of men with clinical urethritis diagnoses (87% total), 
compared with discharge alone. The addition of genital irritation added another 6 (4%) men, 
encompassing 91% of all urethritis diagnoses. The remaining 9% of all clinical diagnoses 
included the symptoms genital itching, genital lesions, and urinary frequency.  
In this study, self-reported urethral discharge was the symptom most predictive of 
urethritis, present in 71% of men with clinical urethritis. Dysuria, the second most prevalent 
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symptom, was reported by 59% of men with urethritis. Only discharge and dysuria were 
significantly associated with a urethritis diagnosis and appear to increase the risk by 2-fold. Men 
with urethritis rarely complained of the remaining 5 symptoms, in which each occurred in 6% 
of men. In fact, only 4% (range 0–6%) of urethritis patients complained of frequency, genital 
irritation, itching, lesions or odor, which were either not associated with urethritis or were more 
likely to be associated with a diagnosis other than urethritis. This suggests that these symptoms 
provide specific information that, excluding discharge or dysuria, support an alternative 
diagnosis (e.g. lesions caused by HPV, etc.).  
Our study suggests that discharge and dysuria are clearly the most important symptoms to 
ask men being evaluated for urethritis. The remaining symptoms of irritation, itching and lesions 
appear to be beneficial only when added to discharge and dysuria as, independently, they were 
not significantly associated with urethritis. Asking about urinary frequency or genital odor, in 
addition to the former symptoms, identified only two additional cases of urethritis suggesting 
there is little utility in adding those symptoms to either the clinical interview or in a symptom 
survey. 
Genital irritation, genital itching, genital lesions, urinary frequency, and urinary odor 
were relatively infrequent, cumulatively comprising only 13% of urethritis diagnoses in differing 
proportions. This suggests that men may have difficulty articulating their symptoms perhaps 
colored by their pre-conceptions of what symptoms an STD “should” feel like. Specifically, men 
may have difficulty differentiating “genital irritation” from “genital itching” and combining them 
into a broader term may be appropriate. For example, in our study, four men admitted to 
irritation, but specifically identified their symptom as “tingling” (data not shown). As a 
simplifying strategy, we suggest the use of a broader, more encompassing term such as “genital 
discomfort” instead of “genital irritation” and/or “genital itching” which would identify 95% of 
AC
CE
PT
ED
  7 
urethritis diagnoses, when combined with urethral discharge and dysuria.  In contrast, adding 
urinary frequency or odor to the list of queried symptoms had little impact on the percent of 
identified urethritis cases (Table 2) and could likely be excluded from urethritis screening. 
Our study has several limitations. In this single-center study, the majority of men in this 
study were African American, which is representative of our clinic population, and therefore 
these findings may not be generalizable to other populations. The GC rate was high in our study, 
and we cannot exclude that our findings may differ in populations with different STI rates and/or 
etiologies of urethritis (e.g. M. genitalium, T. vaginalis, etc), especially outside the U.S. We also 
used a Gram stain cutoff of ≥5 PMNs/HPF (recommended by the European NGU treatment 
guidelines)
13
 in order to maximize the urethritis diagnosis specificity. It is possible that using the 
lower cutoff of ≥2 PMNs/HPF (recommended by the 2015 CDC STD treatment guidelines)4 
could have yielded different results. Although the latter cutoff appears to identify more 
chlamydia diagnoses,
13
 whether it more accurately reflects urethritis remains unclear. Also, our 
study only enrolled men who presented to the STD clinic and we cannot rule out the possibility 
of a selection bias, given our study does not include men presenting to other clinics or mildly 
symptomatic men who did not come in for symptom evaluation.  
In conclusion, in sexually active men who present with genitourinary complaints, a 
history of discharge and/or dysuria should prompt appropriate evaluation and screening for 
urethritis and could identify up to 87% of cases. If combined with discharge and/or dysuria, up to 
95% of urethritis cases could  be identified if genital irritation and/or itching was also present.  
Excluding discharge and dysuria, however, the other symptoms were not independently 
associated with a urethritis. Urinary frequency and odor were poor predictors of urethritis and 
can likely be excluded from symptom queries trying to identify men with symptomatic urethritis. 
These results could form the basis for an effective standardized EMR-based method for 
screening sexually-active men for symptomatic urethritis. 
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Table 1. Frequency of Symptoms Associated with Urethritis and Expert Clinicians’ Valuation of 
the Urethritis Syndrome at Predicting Urethritis in Symptomatic Men 
 
Urethritis 
Symptom 
% in Sx Men  
(n = 194) 
% in Sx Men with 
Urethritis (n = 139) 
 
% in Sx Men without 
Urethritis (n = 55) 
 
Relative Risk 
 (95% CI) 
Expert Scorea 
(Mean ± StDev) 
Discharge 61% 71% 36% 1.96 (1.36–2.82) 1.3 ± 0.48 
Dysuria 50% 59% 27% 2.16 (1.37 – 3.40) 1.7 ± 0.48 
Frequency 7% 6% 9% 0.63 (0.22 – 1.85) 3.8 ± 1.14 
Irritationb 10% 6% 22% 0.26 (0.11 – 0.61) 4.1 ± 0.76 
Itching 7% 5% 11% 0.45 (0.16 – 1.29) 4.6 ± 1.12 
Lesions 10% 6% 20% 0.29 (0.12 – 0.68) 5.9 ± 1.04 
Odor 1% 0% 2% 0.13 (0.0 – 3.22) 6.5 ± 0.78 
Abbreviations: CI, confidence interval; Sx, symptomatic; StDev, standard deviation 
aScore sorted from most important (1) to least important (7) by STD experts (n = 13). 
bGenital irritation includes tingling and non-micturition-associated groin or penile pain. 
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Table 2. Percent of Clinical Urethritis Identified by One or More Symptoms (n = 139) 
Symptom 
     
n (%) Added n (%) Total 
Discharge              99 (71.2%) 
Discharge + Dysuria   
 
  
 
  + 22 (15.9%) 121 (87.1%) 
Discharge + Dysuria +Irritation        + 6 (4.3%) 127 (91.4%) 
Discharge + Dysuria +Irritation + Itching      + 5 (3.6%) 132 (95.0%) 
Discharge + Dysuria +Irritation + Itching + Lesions    + 5 (3.6%) 137 (98.6%) 
Discharge + Dysuria +Irritation  + Itching + Lesions  + Frequency    + 2 (1.4%) 139 (100%) 
Discharge + Dysuria +Irritation  + Itching + Lesions  + Frequency  + Odor + 0 139 (100%) 
Abbreviations: + indicates "and/or"  
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